A large pharma company are developing an IO asset upon UK oncology seeking a range of indication expansions in the UK. They are currently approved for two lines of therapy for a single disease area. The company wanted to understand what would be the net price implications for seeking expansion to other indications to support their financial planning efforts. Net price forecasting within the UK is highly challenging due to the confidentiality around commercial discounts between manufacturers and the NHS.
Situation assessment & uncertainty profiling
Value vs QALY framework development to estimate QALY gains for Product X
Net price calculations for Product X using SoC net prices
Uncertainty profiling & inclusion into net price forecasting
GPI applied its early and price forecasting methodology GPI horizon, to the cost effectiveness market and was able to derive the QALY estimates and thus the ICER to then calculate the net price of product X.
Taking uncertainty considerations into account, GPI was able to provide a base-case and worst-case forecasts, as well as surrounding strategy for supporting indication optimisation to ensure maximum asset revenue for this particular oncology asset.
Share this case study: